Overview

Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Status:
Terminated
Trial end date:
2016-08-31
Target enrollment:
Participant gender:
Summary
Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.
Phase:
Phase 2
Details
Lead Sponsor:
Leo W. Jenkins Cancer Center
Treatments:
Famotidine
Interleukin-2